Abstract

Broadly neutralizing antibodies (bNAbs) are rarely elicited by current human immunodeficiency virus type 1 (HIV-1) vaccine designs, but the presence of bNAbs in naturally infected individuals may be associated with high plasma viral loads, suggesting that the magnitude, duration, and diversity of viral exposure may contribute to the development of bNAbs. Here, we report the isolation and characterization of a panel of human monoclonal antibodies (mAbs) from two subjects who developed broadly neutralizing autologous antibody responses during HIV-1 infection. In both subjects, we identified collections of mAbs that exhibited specificity only to a few autologous envelopes (Envs), with some mAbs exhibiting specificity only to a subset of Envs within the quasispecies of a particular sample at one time point. Neutralizing antibodies (NAbs) isolated from these subjects mapped mostly to epitopes in the Env V3 loop region and the CD4 binding site. None of the individual neutralizing mAbs recovered exhibited the cumulative breadth of neutralization present in the serum of the subjects. Surprisingly, however, the activity of polyclonal mixtures comprising individual mAbs that each possessed limited neutralizing activity, could achieve increased breadth of neutralizing activity against autologous isolates. While a single broadly neutralizing antibody targeting one epitope can mediate neutralization breadth, the findings presented here suggest that a cooperative polyclonal process mediated by diverse antibodies with more limited breadth targeting multiple epitopes also can achieve neutralization breadth against HIV-1.

Highlights

  • The primary goal of most current human immunodeficiency virus type 1 (HIV-1) research efforts has been aimed at isolating and characterizing cross-reactive and potent neutralizing antibodies [1] that can limit or prevent infection in animal models and potentially humans [2]

  • We isolated a total of 90 human monoclonal antibodies (mAbs) from VC10014 and 56 mAbs from VC20013 using Peripheral blood mononuclear cells (PBMCs) obtained from blood samples at four time-points for each donor

  • HIV1-reactive B cell lines were present in about 15% of total wells tested depending on the efficiency of Epstein-Barr virus (EBV)-transformation, and the HIV-1 neutralization frequency of EBV-transformed B cell lines in both subjects ranged from 0.07–0.11%

Read more

Summary

Introduction

The primary goal of most current HIV-1 research efforts has been aimed at isolating and characterizing cross-reactive and potent neutralizing antibodies (bNAbs) [1] that can limit or prevent infection in animal models and potentially humans [2]. Many HIV-1 infected individuals generate NAbs within the first year or two of infection, such antibodies early in the course of infection usually possess limited neutralization breadth [8]. Similar antibodies have rarely been elicited by current vaccine design efforts, but studies have shown that the presence of bNAbs in naturally infected individuals may be associated with high plasma viral loads [13,14]. These observations suggest that in some chronically infected subjects, the magnitude, duration, and diversity of viral exposure may contribute to the development of bNAbs [15]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call